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Abstract
Limited investigations have been conducted on syndemics and HIV continuum of care outcomes. 
Using baseline data from a multi-site, randomized controlled study of HIV-positive injection drug 
users (n=1052), we examined whether psychosocial factors co-occurred, and whether these factors 
were additively associated with behavioral and HIV continuum of care outcomes. Experiencing 
one type of psychosocial problem was significantly (p<0.05) associated with an increased odds of 
experiencing another type of problem. Persons with 3 or more psychosocial problems were 
significantly more likely to report sexual and injection risk behaviors and were less likely to be 
adherent to HIV medications. Persons with 4 or more problems were less likely to be virally 
suppressed. Reporting any problems was associated with not currently taking HIV medications. 
Our findings highlight the association of syndemics not only with risk behaviors, but also with 
outcomes related to the continuum of care for HIV-positive persons.
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INTRODUCTION
One of the three goals of the National HIV/AIDS Strategy (NHAS)(1) is to increase access 
to health care and improve health outcomes for people living with HIV (PLWH). 
Antiretroviral therapy (ART) not only improves health outcomes for HIV-positive persons, 
but also provides substantial protection for HIV-negative sexual partners (2). In July 2013, 
President Obama issued an Executive Order re-emphasizing the importance of addressing 
the HIV continuum of care for PLWH (3). In the US, it is estimated that 66% of PLWH are 
linked to care and that the percentages of persons achieving successful outcomes decline as 
one moves along the continuum of care (i.e., retained in HIV care [37%], prescribed ART 
[33%] and have suppressed viral load [25%]) (4). Addressing the continuum of care, 
including identifying undiagnosed HIV-positive persons, increasing linkage and retention to 
health services, and suppressing viral load is critical for achieving the NHAS goals of 
improving health outcomes of PLWH, and preventing further HIV transmission (1,5).
In the United States (US), persons who inject illicit drugs (IDUs) accounted for an estimated 
11% of diagnosed HIV infections among adults and adolescents in 2011 (5% attributed to 
males who inject drugs, 3% to men who report male-to-male sexual contact and injection 
drug use, and 3% to females who inject drugs). Among male adults and adolescents living 
with diagnosed HIV infection at the end of 2010, 21% of infections were estimated to be 
attributed to injection drug use (14% to injection drug use and 7% to male-to-male sexual 
contact and injection drug use). Among females living with diagnosis of HIV infection, 25% 
were estimated to be attributed to injection drug use (6). Although rates of HIV infection 
among HIV-positive IDUs have decreased over time, they are of concern because of two 
potential modes of HIV transmission - sexual behaviors as well as injection behaviors (7–
14). Research shows that HIV-positive IDUs are generally socially and economically 
marginalized and face life circumstances that present significant challenges for HIV 
prevention efforts including homelessness, violence, addiction, and social exclusion (15–
16).
The term syndemics, first applied in the context of HIV/AIDS by Singer (17), describes an 
interconnected set of problems such as mental health, substance use/abuse, and violence/
abuse that additively increase vulnerability to adverse health outcomes (18–19). Further, 
syndemic theory suggests that these mutually reinforcing health problems are socially 
produced, pointing to poverty and social inequality as the adverse social conditions through 
which health problems emerge, concentrate, and interact (17). Increasingly, syndemic theory 
has been used to explain health disparities among gay, bisexual, and other men who have 
sex with men (collectively referred to as MSM) and people most at risk for poor health 
outcomes. Researchers have found that co-occurring and synergistically interacting 
psychosocial problems are associated with sexual risk behaviors and/or HIV prevalence 
among various samples of MSM (18, 20–24) and other populations such as transgender 
women (25), patients attending an urban STD clinic (26), and women (27). To date, there 
has been limited investigation of syndemics among HIV-positive IDUs and little data 
reporting the associations between syndemics and behaviors such as injection risk behaviors 
and outcomes on the continuum of HIV care (e.g., measures of retention in care, treatment 
uptake, medication adherence, and viral load suppression).
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Previous research has typically included psychosocial factors such as poly-drug use, mental 
health problems, and abuse/violence in the measure of syndemics (18, 20, 21, 23–26, 28–
30). Based on the life circumstances of HIV-positive IDUs which could be attributed to their 
adverse social conditions (15, 16, 31), other relevant problems such as low social support 
(32–34), homelessness (15, 16, 35), and incarceration (15, 36–40) could also be considered 
psychosocial factors (41) that define a syndemic. Using baseline data collected from a large 
sample of HIV-positive IDUs who participated in a randomized controlled behavioral 
intervention trial to address sexual and injection risk behaviors, utilization of HIV care, and 
adherence to HIV medications (42, 43), we examined whether certain psychosocial factors 
were co-occurring, and whether these factors were additively associated with each of the six 
negative behaviors or outcomes such as sexual and injection HIV transmission risk 
behaviors, not being retained in HIV care, not taking HIV medications, not adhering to HIV 
medication regimens, and having detectable viral load. By focusing on syndemics, we move 
away from individual-level determinants of health (15) to a more holistic approach that 
considers broader social and structural-level determinants in understanding risk and health 
behaviors of HIV-positive IDUs.
METHODS
Data
We report baseline data collected from participants of the Intervention for Seropositive 
Injectors – Research and Evaluation (INSPIRE), a randomized controlled trial of an HIV 
prevention intervention designed for HIV-positive IDUs (42, 43). We included 1052 
participants who provided complete responses to questions related to potential syndemic 
factors. The study was conducted in four cities in the United States (Baltimore, Miami, New 
York, and San Francisco) from 2001 through 2005. Participants were recruited using active 
(e.g., street outreach) and passive strategies (e.g., posters and leaflets, word of mouth) in a 
variety of HIV care and community venues including AIDS service organizations, medical 
clinics, methadone clinics, as well as street-based settings. Individuals were eligible for the 
study if they were at least 18 years old, confirmed to be HIV positive by testing of oral 
specimen, reported injection drug use in the past 12 months, and reported having sex with an 
opposite sex-partner in the past 3 months.
Using an audio-computer assisted self-interview (A-CASI), participants were asked 
questions regarding sexual and drug using behaviors, utilization of health care, and 
adherence to HIV medications. Participants also provided an oral fluid sample for 
confirmatory HIV-antibody testing (OraSure, OraSure Technologies, Inc., Bethlehem, PA, 
USA) and a blood specimen for CD4 count and viral load. HIV confirmatory testing was 
performed at local laboratories, and CD4 count and viral load testing was performed at CDC 
laboratories. Participants were reimbursed $30 for their time and effort for the baseline 
appointment. More detailed description of INSPIRE and its methodology has been reported 
elsewhere (42. 43). Study protocols were approved by institutional review boards of CDC 
and collaborating study sites.
Mizuno et al. Page 3
AIDS Behav. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Measures
Psychosocial problems—We assessed six psychosocial problems as potential syndemic 
factors. Poly-drug use was assessed by asking the number of different types of illicit drugs 
participants used in the past 3 months, and then creating a dichotomous variable indicating 
whether 3 or more drugs were used. Experience of abuse was measured by asking whether 
participants have ever been sexually abused (i.e., sexually attacked, raped, or sexually 
abused) or physically abused (i.e., beaten, physically attacked, or physically abused) in 
adulthood. Psychological distress during the previous week was measured by combining the 
depression (7 items), anxiety (6 items), and hostility (5 items) subscales of the Brief 
Symptom Inventory (44) (alpha = 0.95). Each item had five response categories (1=not at 
all, 2=a little…to 5=extremely). Average scores across the 18 items were dichotomized so 
that participants whose average scores were higher than 2 (a little distress) were categorized 
as having psychological distress. Lack of social support was measured by a 5-item scale 
adapted from the social support scale developed by Barrera (45) (alpha = 0.87). Each item 
had five response categories (1=definitely not, 2=probably not…to 5=definitely yes). 
Average score across the 5 items were dichotomized so that participants whose average 
scores were less than 3 (maybe) were categorized as perceiving low social support. 
Homelessness was assessed by asking whether participants slept at least one week in a 
squatting place, abandoned building, car, homeless shelter, park or street in the past 12 
months. Incarceration history was assessed by asking whether participants had been in jail, 
prison, or a correctional facility in the past 6 months.
Behavioral/health outcomes—For sexual transmission risk behavior, we assessed 
whether participants engaged in any vaginal or anal sex without condoms with HIV-negative 
or unknown HIV status sex partners in the past 3 months. For injection risk behavior, we 
assessed whether participants lent a used needle to or shared injection equipment (cooker, 
cotton, or rinse water) with HIV-negative or unknown HIV status drug use partners in the 
past 3 months. HIV care visit was used as a measure of retention in HIV care, and for this, 
we assessed whether participants self-reported having any visits to their HIV health care 
providers in the past 6 months. HIV medication use was used as a measure of HIV 
medication uptake, and for this, we assessed whether participants were currently taking any 
HIV medications. For medication adherence, we assessed prior day adherence to dosage as a 
continuous rate and dichotomized it into ≥90% adherence (yes/no) (46). Viral load measured 
from blood specimens were dichotomized into undetectable (<400 copies/mL) versus 
detectable. For ease of interpretation of results, we coded each of the behavioral and health 
outcomes so that those coded as 1 represented a negative outcome (i.e., engaging in risky 
sexual or injection behavior, not having any visits to their HIV health care providers, not 
taking any HIV medications, not adhering to their HIV medication regimen, or having a 
detectable viral load).
Socio-demographic variables—Socio-demographic variables examined included age, 
biological sex at birth (male vs. female), race/ethnicity (Non-Hispanic white, Non-Hispanic 
black, Hispanic, and other), education (high school or more vs. less than high school), 
income ($5,000 or more per year vs. less than 5,000 per year, median-split), and city 
(Baltimore, Miami, New York and San Francisco).
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Analytic strategy
First, we examined the extent to which participants reported experiencing each of the 
psychosocial problems. We used bivariate logistic regression models to assess whether 
reporting one type of psychosocial problem was associated with reporting of other types of 
problems, and also whether reporting each of the psychosocial problems was associated with 
each of the six behavioral and health outcomes. We then examined the extent to which 
participants reported multiple psychosocial problems by developing a count score of the 
number of psychosocial problems (from 0 to 6) and assessed its frequency distribution. For 
ease of further analyses and interpretation and because relatively fewer people reported 
having five (n=54, 5.1%) or six problems (n=10, 1.0%), we combined cases reporting 4 to 6 
problems into one group (n=180, 17.1%). We used the Mantel-Haenszel chi-square to test 
for linear association between the number of psychosocial problems and the prevalence of 
each behavioral and health outcome. We then used multivariable logistic regression models 
to test which numbers of psychosocial problems were associated with each outcome. For 
these models, we treated the number of problems as a series of binary variables with zero 
problems as a reference category, and we also controlled for demographic variables such as 
age, sex, race, income, education, and city.
RESULTS
Sample Characteristics
Table 1 summarizes the characteristics of HIV-positive IDUs in the sample (n=1052). The 
sample was predominantly male, African American, and of extremely low socioeconomic 
status. Almost a third of the sample reported engaging in sexual and injection risk behaviors 
in the past 3 months. One in five reported not having any visits to their HIV health care 
providers in the past 6 months and 44% reported not currently taking HIV medications. 
Among those who were taking HIV medications who also provided valid adherence data 
(n=501), a quarter reported less than 90% adherence to their HIV medications regimens on 
the previous day. Only one out of five of participants who provided blood samples at 
baseline had an undetectable viral load.
Co-occurring Psychosocial Problems
Table 1 also shows the percentage of participants who reported experiencing each of the 
psychosocial problems. Poly-drug use in the past 3 months was reported by almost 60% of 
the sample. About a half reported experiencing abuse in adulthood. Thirty-seven percent 
were categorized as having psychological distress. About a third reported experiencing 
homelessness in the past 12 months. Incarceration in the past 6 months was reported by 
about a quarter of the sample. Thirteen percent were categorized as perceiving low social 
support.
Table 2 shows the results of bivariate logistic regression analyses testing the associations 
among experiences of psychosocial problems. These results indicate that experiencing one 
type of problem was often significantly (p<0.05) associated with an increased odds of 
experiencing several other types of problem. The association between psychosocial 
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problems was minimal for incarceration, which was associated only with homelessness. 
Further, low social support and poly-drug use were not associated.
Table 3 shows the results of bivariate logistic regression analyses testing the association 
between each of the psychosocial problems and each of the behavioral and health outcomes. 
With the exception of adulthood abuse, each psychosocial problem was significantly 
(p<0.05) associated with an increased odds of experiencing at least three negative behavioral 
or health outcomes. Those who had been homeless had increased odds of experiencing all 
six negative outcomes, and each psychosocial problem was associated with increased odds 
of reporting sexual risk behavior.
Table 4 shows the frequency distribution of the number of psychosocial problems reported; 
only about 10% reported 0 problems, 23% reported one type, about a third reported two 
types, almost 20% reported three types, and 17% reported four to six types of problems.
Association between Number of Psychosocial Problems and Behavioral/Health Outcomes
Table 4 also shows bivariate associations between the number of psychosocial problems and 
each of the behavioral and health outcomes. For example, 14% of those who reported zero 
psychosocial problems engaged in sexual risk behavior in the past 3 months. The percentage 
was 22, 23, 30, and 47% for those who reported one, two, three, or four to six types of 
problems, respectively. As indicated in the Mantel-Haenszel chi-square test statistics, there 
was a significant linear association between the number of psychosocial problems and 
prevalence of the negative behavioral or health outcomes.
Table 5 reports the results of multivariable logistic regression analyses showing the number 
of psychosocial problems that was associated with the odds of each behavioral/health 
outcome, controlling for age, sex, race, income, education, and city. For most negative 
behavioral and health outcomes (except for “not currently taking HIV medications where 
reporting any problems was each associated with the outcome), no significant differences 
were observed between those who reported one or two problems and those who reported no 
problems. For “no HIV care visit in the past 6 months,” no significant differences were 
observed between those who reported no problems and those who reported any number of 
problems, although the difference between zero and “four to six problems” approached 
statistical significance (AOR=2.05, p=0.052).
For sexual risk behavior, reporting three problems was associated with a greater than 2-fold 
increase in the odds of engaging in sexual risk behavior and reporting four to six problems 
was associated with a greater than 4-fold increase in the odds as compared to reporting no 
problems. For injection risk behavior, reporting three problems was associated with a greater 
than 2-fold increase in the odds of engaging in injection risk behavior and reporting four to 
six problems was associated with almost a 5-fold increase in the odds as compared to 
reporting no problems. Reporting any number of problems was each associated with a 
greater than 2-fold increase in the odds of not currently taking HIV medications as 
compared to reporting no problems. Reporting three or four to six problems was associated 
with a 2 to 2.5-fold increase in the odds of non-adherence as compared to reporting no 
Mizuno et al. Page 6
AIDS Behav. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
problems. Finally, for detectable viral load, reporting four to six problems was associated 
with a greater than a 2-fold increase in the odds as compared to reporting no problems.
DISCUSSION
This study is one of the first to quantitatively explore syndemic vulnerability among HIV-
positive IDUs, and also one of the first to examine how co-occurring psychosocial problems 
are additively associated with outcomes related to the HIV continuum of care. In our sample 
of HIV-positive IDUs which was comprised primarily of African Americans and males, 
many reported more than one psychosocial problem. We found that generally experiencing 
one type of psychosocial problem was significantly (p<0.05) associated with an increased 
odds of experiencing another type of problem and also with an increased odds of negative 
behavioral or health outcomes. The syndemic pattern observed in this sample, i.e., the 
pattern of co-occurring psychosocial problems creating additive vulnerability for poor health 
outcomes, was similar to that seen in other populations (23, 24). Furthermore, in our sample, 
syndemic problems were associated with HIV transmission risk behaviors, HIV care 
behaviors, and detectable viral load measured from participants’ blood specimens. We 
observed a linear association showing that greater numbers of psychosocial problems were 
significantly associated with higher prevalence of negative behavioral or health outcomes.
We also found that each negative outcome had what may be termed as a threshold of 
syndemic vulnerability or a specific number of psychosocial problems significantly 
associated with it. That is, for sexual and injection risk behaviors and medication adherence, 
persons who reported three or more psychosocial problems evidenced significantly elevated 
odds of these outcomes while those who reported one or two did not have significantly 
elevated odds. For detectable viral load, the threshold was four to six problems, while any 
number of problems was significantly associated with elevated odds of not currently taking 
HIV medication. For health care visit, although no specific number of problems was 
significantly associated with its negative outcome, there was a tendency for persons with 
four to six problems to be more vulnerable (p=0.052). These findings suggest the utility of a 
syndemic framework in identifying the vulnerability threshold, and experience of three or 
four of these problems might constitute the threshold for most of the negative behavioral and 
health outcomes among these HIV-positive IDUs.
Syndemics theory posits that the interaction of health problems emerges because of adverse 
social conditions such as poverty, stigmatization, and oppressive social relationships (19). 
Indeed, research on IDUs often points to how their “risk environment” is socially produced. 
For example, Rhodes and colleagues (47) point to social structural factors such as 
neighborhood deprivation and disadvantage, social and economic inequities, and social 
stigma and discrimination as critical in the production of HIV risk among IDUs. Emerging 
work has included a broader social structural perspective when examining syndemics among 
MSM. For example, Ferlatte and colleague (48) found that marginalization of gay and 
bisexual men (e.g., anti-gay experience) was cumulatively associated with psychosocial 
issues (e.g., emotional distress, social isolation), which, in turn, were additively associated 
sexual risk behavior. Similarly, research among minority MSM (49, 50) found evidence of a 
syndemic of adverse social experiences such as racism and homophobia. Future research on 
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syndemics among IDUs could include variables drawn from a broader social structural 
framework (e.g., poverty, residential segregation, IDU/HIV stigma, discrimination) and 
examine how these variables might contribute to the formation of an interconnected set of 
psychosocial problems experienced among IDUs or how these variables could themselves be 
additively associated with negative behavioral and health outcomes.
Other future research topics might include the identification of mechanisms through which 
multiple psychosocial problems are associated with negative outcomes and understanding 
which problems most often cluster together among persons with multiple psychosocial 
vulnerabilities. The U.S. Department of Health and Human Services recently released 
recommendations that all HIV-positive persons be prescribed antiretroviral (ARV) 
treatment, regardless of CD4 count (51). Thus, syndemic research that includes HIV 
continuum of care outcomes might include all HIV-positive persons, not just HIV-positive 
IDUs. With this broader scope, future research can also aim to identify which psychosocial 
problems are most important for which populations.
Limitations of these analyses are as follows. First, we conducted secondary analysis of data 
collected from an intervention trial which was not designed to test syndemics and HIV care 
continuum outcomes. In addition, our sample was a convenience sample; thus results may 
not be generalizable to all HIV-positive IDUs. In terms of measures, we lacked a measure of 
childhood sexual abuse which other syndemic research has examined, and abuse in 
adulthood appears to be a weak measure and is less associated with other syndemic factors 
and most other outcomes. Our measures of psychological distress were not clinical measures 
and our measures of the continuum of care were developed before the more recent work 
defining these outcomes (52). Also, the measures of psychosocial problems used measures 
that assessed problems in various time points (e.g., polydrug use in the past 3 months, 
psychosocial distress in the previous week, homelessness in the past 12 months, etc.) This 
variation may be an issue in exploring syndemic phenomena as experienced at one point in 
time. It is also important to note that no direction of causality can be implied by our cross-
sectional analyses. While the literature tends to frame syndemics as precursors to public 
health problems, the reverse also could be true or a third variable could affect both sets of 
constructs. Finally, the data we used here were collected in 2001–2005, before ARV 
treatments were recommended for all HIV-positive patients. Thus, the data on HIV 
medication uptake and viral load should be interpreted with caution.
In summary, our analyses expand not only the populations considered in a syndemic 
framework, but also the outcomes to include HIV continuum of care outcomes such as 
utilization of HIV care, uptake of HIV medication, and suppressed viral load. Our findings 
endorse the association of syndemics not only with risk behaviors, but also with behaviors 
related to the continuum of care for HIV-positive persons. The breadth of HIV risk and care 
behaviors associated with psychosocial syndemic factors indicates that they are likely 
important factors for researchers to understand. Addressing these factors in various public 
health interventions or supporting program collaboration and service integration to provide 
multiple prevention and health care services at one time or at a single venue (36) could help 
to change key behaviors linked to both HIV risk and HIV care outcomes.
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